Cardiology research projects
Clinique de Cardiologie Lanaudière actively participates in large-scale national and international clinical research projects. These studies aim to improve the understanding, diagnosis, and treatment of cardiovascular diseases, with a constant focus on innovation and quality of care.
Research experience
Centre d’Investigation Clinique (CIC)
Principal Investigator
BalanceD-HF (2025) — Phase III, randomized, double-blind trial evaluating the effect of the combination of balcinrenone and dapagliflozin on heart failure events and cardiovascular mortality in patients with heart failure and renal dysfunction.
ATTAIN-Outcomes
The ATTAIN-Outcomes study will test the safety and effectiveness of the investigational drug for people living with cardiovascular disease (CVD), chronic kidney disease (CKD), or both. The investigational drug being tested in this study may reduce the risk of heart attack, stroke, and heart failure in patients with CVD, CKD, or both.
COLCOT-T2D (2024) —Randomized trial evaluating the combined effect of colchicine and aspirin on cardiovascular events in patients with type 2 diabetes without a history of cardiovascular disease.
Dal-GenE-2 (2024) — Phase III, randomized, controlled study assessing the efficacy of dalcetrapib in reducing major cardiovascular events in post-acute coronary syndrome patients carrying the AA genotype of the ADCY9 gene.